Cassava Sciences, Inc. carries a market capitalization of 63.77M, placing it among publicly traded companies globally. Its enterprise value stands at 125,070.00, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 63.77M |
| Enterprise Value | 125,070.00 |
Cassava Sciences, Inc. currently has 48.31M shares outstanding.
| Shares Outstanding | 48.31M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.19 |
| P/TBV Ratio | 1.29 |
| P/FCF Ratio | -3.02 |
| P/OCF Ratio | -2.96 |
Cassava Sciences, Inc. maintains a current ratio of 2.23, meaning it holds 2.2x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 2.23 |
| Quick Ratio | 2.18 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -65.95 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Cassava Sciences, Inc.'s stock has declined approximately -35.60976% over the past 52 weeks. The 50-day moving average sits at 2.12, while the 200-day moving average is 2.51.
| Beta (5Y) | N/A |
| 52-Week Price Change | -35.60976% |
| 50-Day Moving Average | 2.12 |
| 200-Day Moving Average | 2.51 |
| Average Volume (20 Days) | N/A |
EBITDA reached -95.19M, while operating income came in at -96.13M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -96.13M |
| Pretax Income | -90.97M |
| Net Income | -90.97M |
| EBITDA | -95.19M |
| EBIT | -96.13M |
| Earnings Per Share (EPS) | -1.88 |
Total book value stands at -496.04M, with working capital of 53.88M providing operational flexibility.
| Cash & Cash Equivalents | 95.50M |
| Total Debt | N/A |
| Net Debt | -95.50M |
| Equity (Book Value) | -496.04M |
| Book Value Per Share | -10.27 |
| Working Capital | 53.88M |
Cassava Sciences, Inc. produced -32.25M in operating cash flow over the past twelve months. After subtracting -581,000.00 in capital expenditures, free cash flow totaled -32.83M - equivalent to -0.68 per share.
| Operating Cash Flow | -32.25M |
| Capital Expenditures | -581,000.00 |
| Free Cash Flow | -32.83M |
| FCF Per Share | -0.68 |
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 0.25 |
| FCF Yield | -33.12 |
Cassava Sciences, Inc.'s most recent stock split took place on May 10, 2017 with a 7:1 split ratio.
| Last Split Date | 5/10/2017 |
| Split Ratio | 7:1 |
Cassava Sciences, Inc. posts an Altman Z-Score of -6.70, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -6.70 |